



(12) Translation of
European patent specification

(11) NO/EP 3271357 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61K 31/519 (2006.01)
A61P 9/10 (2006.01)
A61P 13/12 (2006.01)
C07D 487/04 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.03.23
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.11.27
(86)	European Application Nr.	16715122.4
(86)	European Filing Date	2016.03.17
(87)	The European Application's Publication Date	2018.01.24
(30)	Priority	2015.03.18, GB, 201504565
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA ; MD
(73)	Proprietor	Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, Japan
(72)	Inventor	AHMED, Saleh, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia BARKER, Gregory, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia CANNING, Hannah, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia DAVENPORT, Richard, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia HARRISON, David, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia JENKINS, Kerry, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia LIVERMORE, David, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia WRIGHT, Susanne, c/o Takeda Cambridge Limited418 Cambridge Science Park, Cambridge CB4 0PZ, Storbritannia KINSELLA, Natasha, 6 Leyburn CloseCambridge, CB1 9XR, Storbritannia

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **FUSED BICYCLIC HETEROARYL DERIVATIVES HAVING ACTIVITY AS PHD INHIBITORS**


(56) References

Cited: WO-A1-2014/030716
WO-A1-2011/090127
EP-A1- 0 121 341
US-A1- 2011 077 267

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. En forbindelse med formel (I)



5 hvori

X^1 representerer N; X^2 representerer N; X^3 representerer C; Y^1 representerer CH;

R^1 representerer hydrogen, halogen, C_1 - C_6 alkyl, C_3 - C_6 cykloalkyl, C_1 - C_6 alkoksy C_1 - C_6 alkyl, C_1 - C_6 hydroksyalkyl, $-OR^4$, $-SR^4$, $-C(O)R^4$, $-C(O)OR^4$,
 10 $-(CH_2)_mNHC(O)R^4$, $-(CH_2)_mNHC(O)OR^4$, $-NHC(O)NHR^4$, $-NHSO_2R^4$, $-C(O)NR^5R^6$, $-(CH_2)_mNR^5R^6$, $-SO_2NR^5R^6$ eller en 4- til 9-leddet heterocyklyl (ikke-substituert eller substituert med minst én substituent uavhengig valgt fra okso, C_1 - C_6 alkyl, C_1 - C_6 alkylkarbonyl, C_1 - C_6 alkoksy, C_3 - C_6 cykloalkyl, C_1 - C_6 alkoksykarbonyl, $-(CH_2)_pNR^7R^8$ og $C(O)NR^7R^8$);

15 m er 0 eller 1;

p er 0 eller 1;

R^4 representerer hydrogen, C_1 - C_6 alkyl (ikke-substituert eller substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, C_1 - C_6 halogenalkyl, C_1 - C_6 alkoksy, C_3 - C_6 cykloalkyl, C_6 - C_{10} aryl, NR^9R^{10} , oksetanyl, oksolanyl og oksanyl), C_3 - C_6 cykloalkyl (ikke-substituert eller substituert med minst én substituent uavhengig valgt fra halogen, cyano og C_1 - C_6 alkyl), C_6 - C_{10} aryl eller en 4- til 7-leddet heterocyklyl (ikke-substituert eller substituert med minst én C_1 - C_6 alkyl);

R^5 og R^6 , uavhengig av hverandre, representerer hydrogen, C_1 - C_6 alkyl (ikke-substituert eller substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, C_1 - C_6 alkoksy, C_3 - C_6 cykloalkyl, $NR^{11}R^{12}$, C_6 - C_{10} aryl, 5- til 10-leddet heteroaryl og 4- til 7-leddet heterocyklyl, idet hver av aryl-, heteroaryl- og heterocyklylsubstituentene eventuelt er substituert med minst én substituent uavhengig valgt fra halogen, okso, C_1 - C_6 alkyl, C_1 - C_6 alkoksy, C_1 - C_6 alkoksykarbonyl og fenyl), C_1 - C_6 alkylkarbonyl, C_3 - C_6 cykloalkyl, C_6 - C_{10} aryl, 5- til 10-leddet heteroaryl, 4- til 7-leddet heterocyklyl, idet hver av aryl-, heteroaryl- og heterocyklylgruppene eventuelt er substituert med minst én

substituent uavhengig valgt fra halogen, C₁-C₆ alkyl, C₁-C₆ alkoksy, og C₁-C₆ alkylkarbonyl,

eller R⁵ og R⁶ kan sammen med nitrogenatomet hvilket de er bundet til, danne en

5 4- til 7-leddet mettet heterocyklisk ring ikke-substituert eller substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, okso og C₁-C₆ alkoksy;

R⁷ og R⁸, uavhengig av hverandre, representerer et hydrogenatom eller en C₁-C₆ alkyl eller C₃-C₆ cykloalkylgruppe, eller R⁷ og R⁸ kan sammen med
10 nitrogenatomet hvilket de er bundet til, danne en 4- til 7-leddet mettet heterocyklisk ring eventuelt substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, okso og C₁-C₆ alkoksy;

R⁹ og R¹⁰, uavhengig av hverandre, representerer et hydrogenatom eller en C₁-C₆ alkyl eller C₃-C₆ cykloalkylgruppe, eller R⁹ og R¹⁰ kan sammen med
15 nitrogenatomet hvilket de er bundet til, danne en 4- til 7-leddet mettet heterocyklisk ring eventuelt substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, okso og C₁-C₆ alkoksy;



R¹¹ og R¹², uavhengig av hverandre, representerer et hydrogenatom eller en C₁-C₆ alkyl eller C₃-C₆ cykloalkylgruppe;





20 Y² representerer C eller N;

når Y² representerer C, representerer R² et hydrogen- eller halogenatom, eller en C₁-C₃ alkyl- eller aminogruppe;

når Y² representerer N, er R² fraværende;


R³ representerer en gruppe med formel (II) til (VIII)





5

eller



hvor i formlene (II) til (VIII) er n 0 eller et helt tall fra 1 til 4, Z representerer CH eller N,

10 R^a representerer halogen, cyano, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl eller C_3 - C_6 cykloalkyl, hver av R^b , R^c , R^d og R^e uavhengig representerer hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoksy, C_1 - C_6 halogenalkyl, C_3 - C_6 cykloalkyl eller $NR^{13}R^{14}$, og hver R^f uavhengig representerer halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoksy, C_1 - C_6 halogenalkyl, C_3 - C_6 cykloalkyl eller $NR^{13}R^{14}$; og

15 R^{13} og R^{14} , uavhengig av hverandre, representerer et hydrogenatom eller en C_1 - C_6 alkyl eller C_3 - C_6 cykloalkylgruppe, eller R^{13} og R^{14} kan sammen med nitrogenatomet hvilket de er bundet til, danne en 4- til 7-leddet mettet heterocyklisk ring eventuelt substituert med minst én substituent uavhengig valgt fra halogen, hydroksyl, okso og C_1 - C_6 alkoksy;

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1, hvori R^1 representerer

- (i) hydrogen,
- 5 (ii) klor,
- (iii) metyl,
- (iv) cyklopropyl,
- (v) metoksymetyl,
- (vi) hydroksymetyl,
- 10 (vii) $-OR^4$,
- (viii) $-SR^4$,
- (ix) $-C(O)R^4$,
- (x) $-C(O)OR^4$,
- (xi) $-(CH_2)_mNHC(O)R^4$,
- 15 (xii) $-(CH_2)_mNHC(O)OR^4$,
- (xiii) $-NHC(O)NHR^4$,
- (xiv) $-NHSO_2R^4$,
- (xv) $-C(O)NR^5R^6$,
- (xvi) $-(CH_2)_mNR^5R^6$,
- 20 (xvii) $-SO_2NR^5R^6$, eller
- (xviii) en 4- til 9-leddet heterocyklyl omfattende ett eller to ring-heteroatomer uavhengig valgt fra nitrogen og oksygen som enten er ikke-substituert eller er substituert med én eller to substituenten uavhengig valgt fra

okso, C₁-C₄ alkyl, C₁-C₂ alkylkarbonyl, C₁-C₂ alkoksy, cyklopropyl, C₁-C₄ alkoksykarbonyl, -(CH₂)_pNR⁷R⁸ og C(O)NR⁷R⁸.

3. Forbindelse ifølge krav 1, hvori R¹ representerer
 5 -(CH₂)_mNHC(O)R⁴ eller -(CH₂)_mNR⁵R⁶ og m er 0.
4. Forbindelse ifølge krav 1, hvori R⁴ representerer hydrogen, C₁-C₃ alkyl (ikke-substituert eller substituert med én, to eller tre substituent uavhengig valgt fra fluor, hydroksyl, trifluormetyl, C₁-C₂ alkoksy, cyklopropyl, fenyl, NR⁹R¹⁰, oksetanyl, oksolanyl og oksanyl), C₃-C₄ cykloalkyl (ikke-substituert eller substituert med én eller
 10 to substituent uavhengig valgt fra fluor, cyano og C₁-C₂ alkyl), fenyl eller en 4- til 6-leddet heterocyklyl (ikke-substituert eller substituert med én eller to C₁-C₆ alkyl-grupper).
- 15 5. Forbindelse ifølge krav 1, hvori R⁵ og R⁶, uavhengig av hverandre, representerer
 - (i) hydrogen,
 - (ii) C₁ til C₅ alkyl (ikke-substituert eller substituert med én, to, tre eller fire substituent uavhengig valgt fra fluor, hydroksyl, metoksy, cyklopropyl, NR¹¹R¹², fenyl, 5- til 6-leddet heteroaryl og 4- til 6-leddet heterocyklyl, idet
 20 hver av aryl-, heteroaryl- og heterocyklylsubstituentene eventuelt er substituert med én, to, tre eller fire substituent uavhengig valgt fra fluor, klor, okso, metyl, metoksy, C₁-C₄ alkoksykarbonyl og fenyl),
 - (iii) metylkarbonyl,
 - (iv) cyklopropyl,
 25
 - (v) fenyl,
 - (vi) 5- til 6-leddet heteroaryl, eller
 - (vii) 4- til 6-leddet heterocyklyl,
- hver av aryl-, heteroaryl- og heterocyklylgruppene (grupper (v), (vi) og (vii) ovenfor)
 30 er eventuelt substituert med én, to, tre eller fire substituent uavhengig valgt fra

metyl, metoksy og C₁-C₂ alkylkarbonyl.

6. Forbindelse ifølge krav 1, hvori R³ representerer en gruppe med formel (II) eller en gruppe med formel (IV).


5

7. Forbindelse ifølge krav 1, hvori R^a representerer cyano.

8. Forbindelse ifølge krav 1, hvori R³ representerer en gruppe med formel (II) hvori R^a representerer cyano, R^c representerer metyl, og hver av R^b, R^d og R^e uafhængig representerer hydrogen, fluor eller metyl.

10

9. Forbindelse ifølge krav 1 med formel (Ia)



15

hvori R¹ representerer NHC(O)R⁴ eller NR⁵R⁶;

E er et nitrogenatom eller CR^b;

R^b og R^e, uafhængig av hverandre, representerer et hydrogen- eller fluoratom;

R^c og R^d, uafhængig av hverandre, representerer et hydrogen-, fluor- eller kloratom eller en metylgruppe;

20

R⁴ representerer en C₁-C₃ alkyl eller C₃-C₆ cykloalkylgruppe; og

R⁵ og R⁶ hver representerer et hydrogenatom.

10. Forbindelse med formel (I) som definert i krav 1, som er:

5-(2,4-diklorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;

5-(4-klorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;

4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-metyl-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

5 2-fluor-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

2,6-difluor-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

3-fluor-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

3-metyl-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

5-(4-klor-2-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;

10 2-klor-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-(trifluormetyl)benzonitril;

5-(4-klor-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;

2-metyl-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

6-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-pyridin-3-karbonitril;

15 5-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-pyridin-2-karbonitril;

4-{[1,2,4]triazolo[1,5-*c*]pyrimidin-5-yl}benzonitril;

2-fluor-4-{[1,2,4]triazolo[1,5-*c*]pyrimidin-5-yl}benzonitril;

4-{6-metyl-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

2-fluor-4-{6-metyl-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

20 5-{7-klor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-6-metylpyridin-2-karbonitril;

5-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}pyrimidin-2-karbonitril;

- 5- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ pyrazin-2-karbonitril;
- 2,3-difluor-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 3-fluor-5- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ -pyridin-2-karbonitril;
- 4-metyl-5- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ -pyridin-2-karbonitril;
- 5 3,5-dimetyl-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzointrile;
- 6- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ pyridazin-3-karbonitril;
- 6-metyl-5- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ -pyridin-2-karbonitril;
- 2-fluor-5-metyl-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 3-klor-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 10 3-metoksy-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 5-metyl-6- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ -pyridin-3-karbonitril;
- 3-etyl-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 3-fluor-5-metyl-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 3-amino-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 15 3-brom-4- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 1- $\{[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ -piperidin-4-karbonitril;
- 4-[7-(hydroksymetyl)- $[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}$]benzonitril;
- metyl 5-(4-cyanofenyl)- $[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-7-karboksylat}$;
- 5-(4-cyanofenyl)- $[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-7-karboksylsyre}$;
- 20 4- $\{7\text{-cyklopropyl}-[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}\}$ benzonitril;
- 4-[7-(pyrrolidin-1-karbonyl)- $[1,2,4]\text{triazolo}[1,5-a]\text{pyridin-5-yl}$]benzonitril;

5-(4-cyanofenyl)-*N*-(2-metoksyetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

4-{7-[(2*S*)-2-metylpyrrolidin-1-karbonyl]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

5 4-[7-(3-metylpyrrolidin-1-karbonyl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

5-(4-cyanofenyl)-*N*-(3-metoksyfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

10 *N*-[2-(3-klorfenyl)etyl]-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

N-[2-(4-klorfenyl)etyl]-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-[2-(3-metoksyfenyl)etyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

15 *N*-(3-klorfenyl)-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

N-(4-klorfenyl)-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-(6-metylpiridazin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

20 5-(4-cyanofenyl)-*N*-(2-metylpirimidin-5-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

N-[(3-klorfenyl)metyl]-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

N-[(4-klorfenyl)metyl]-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

25 5-(4-cyanofenyl)-*N*-[(3-metoksyfenyl)metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-metyl-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

N-butyl-5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-[(1-metyl-1*H*-imidazol-4-yl)metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5 5-(4-cyanofenyl)-*N*-[(1-metyl-1*H*-pyrazol-4-yl)metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

tert-butyl 3-({[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]formamido}metyl)azetidin-1-karboksylat;

10 5-(4-cyanofenyl)-*N*-[2-(morfolin-4-yl)etyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-[2-(4-metylpiperazin-1-yl)etyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-(propan-2-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

15 5-(4-cyanofenyl)-*N*-(cyklopropylmetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-(oksetan-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-(oksetan-3-ylmetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

20 5-(4-cyanofenyl)-*N*-(1-metylazetidin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

5-(4-cyanofenyl)-*N*-(2-hydroksyetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-karboksamid;

4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

25 4-{7-[(cyklopropylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(2-metoksyetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-[7-(etylamino)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

4-{7-[(oksan-4-ylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(oksolan-3-ylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(2,2-difluoretyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

5 4-{7-[(oksetan-3-ylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(3,3,3-trifluorpropyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

10 4-(7-{[3-(morfolin-4-yl) propyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-{7-[(2-hydroksy-2-metylpropyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(3-metoksypropyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

4-{7-[(oksolan-2-ylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

15 4-(7-{[2-(dimetylamino)etyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-[7-(benzylamino)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

4-(7-{[(2-fluorfenyl)metyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

20 4-(7-{[(3-fluorfenyl)metyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-(7-{[(4-fluorfenyl)metyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-[7-(cyklopropylmetoksy)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

25 4-[7-(benzyloksy)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

tert-butyl-N-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;

N-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

N-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-karboksamid;

5 *N*-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]benzamid;

tert-butyl-N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;

2-fluor-4-{7-[(oksetan-3-ylmetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

10 2-fluor-4-{7-[(3,3,3-trifluorpropyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

2-fluor-4-(7-{[(3-metyloksetan-3-yl)metyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

15 2-fluor-4-(7-{[(3-fenyloksetan-3-yl)metyl]amino}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-{7-[2-(dimetylamino)etoksy]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-fluorbenzonitril;

2-fluor-4-{7-[2-(pyrrolidin-1-yl)etoksy]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

20 2-fluor-4-[7-(oksolan-2-ylmetoksy)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

2-fluor-4-{7-[2-(2-okso-pyrrolidin-1-yl)etoksy]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

25 2-fluor-4-[7-(oksolan-3-ylmetoksy)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

2-fluor-4-[7-(2-okso-pyrrolidin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

2-fluor-4-[7-(2-okso-1,3-oksazolidin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-*N*-metyl-acetamid;

5 2-fluor-4-[7-(morfolin-4-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

2-fluor-4-[7-(3-metoksyazetidin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

4-[7-(3-metoksyazetidin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

10 4-(7-{2-oksa-6-azaspiro[3.3]heptan-6-yl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

N-[5-(4-cyano-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

tert-butyl 4-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]piperazin-1-karboksylat;

15 *tert*-butyl 6-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2,6-diazaspiro[3.3]heptan-2-karboksylat;

metyl-*N*-[5-(4-cyano-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;

4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-fluorbenzonitril;

20 4-{6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-sulfonamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]benzen-sulfonamid;

25 3-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-1-fenylurea;

N-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3-metoksypropanamid;

N-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-fenylacetamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3,3,3-trifluorpropanamid;

5 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-metoksyacetamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklobutan-karboksamid;

10 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-(oksan-4-yl)acetamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-metylcyklopropan-1-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-(piperidin-1-yl)acetamid;

15 (2*S*)-*N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksolan-2-karboksamid;

(2*R*)-*N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksolan-2-karboksamid;

20 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-(dimetylamino)acetamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksolan-3-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-1-metylcyklopropan-1-karboksamid;

25 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksan-3-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-4-metyloksan-4-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3-etyloksetan-3-karboksamid;

5 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksetan-3-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2,2-difluor-cyklopropan-1-karboksamid;

10 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-cyklopropyl-acetamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-metoksy-2-metylpropanamid;

1-cyano*N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-1-karboksamid;

15 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3-fluorcyklobutan-1-karboksamid;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-(oksetan-3-yl)acetamid;

20 *N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-karboksamid;

N-[5-(4-cyano-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3,3,3-trifluorpropanamid;

4-[7-(benzylsulfanyl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

25 5-(4-cyanofenyl)-*N*-(cyklopropylmetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-sulfonamid;

5-(4-cyanofenyl)-*N*-[2-(dimetylamino)etyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-sulfonamid;

5-(4-cyanofenyl)-*N*-[2-(dimetylamino)etyl]-[1,2,4]triazolo[1,5-*a*]pyridin-7-sulfonamid;

2-(azetidin-1-yl)-*N*-[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

5 4-{7-amino-6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

5-(4-etylnylfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;

4-(7-{[(propan-2-yl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

10 4-(7-{[(2,2,2-trifluoretyl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-(7-{[(oksetan-3-yl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-(7-{[(oksetan-3-yl)metyl]amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

15 4-(7-{[(2,2-difluoretyl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-[7-{[(3-klorfenyl)metyl]amino}metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

20 4-(7-{[(cyklopropylmetyl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

4-[7-{[(3-metoksyfenyl)metyl]amino}metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;

4-{7-[(3-metoksyazetidin-1-yl)metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

25 4-(7-{[(oksolan-3-yl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

- 4-(7-{[(oksolan-3-ylmetyl)amino]metyl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;
- 4-{7-[(cyklopropylamino)metyl]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- cyklopropylmetyl-N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- 2-metoksyetyl-N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- 1-metylpiiperidin-4-yl N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- 3-(dimetylamino)propyl N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- 2-(dimetylamino)etyl N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- oksolan-3-yl N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;
- 4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-metylbenzonitril;
- 4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-fluorbenzonitril;
- 4,6-dimetyl-5-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}pyrimidin-2-karbonitril;
- 5-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-6-metylpyridin-2-karbonitril;
- 5-(4-klor-3-metoksyfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin;
- 2-fluor-4-{6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 4-{6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-metylbenzonitril;
- 3-fluor-4-{6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 4-{7-hidroksy-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

- 2-fluor-4-{7-hydroksy-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-fluor-5-metylbenzonitril;
- 4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}piperazin-1-karbonitril;
- 3,5-difluor-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 5 2-fluor-3-metyl-4-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 4-[7-(metoksymetyl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;
- N*-{[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]metyl}acetamid;
- N*-{[5-(4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]metyl}cyklopropan-
karboksamid;
- 10 4-{6-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;
- 4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-fluor-3-metylbenzonitril-
hydroklorid;
- 5-{6-fluor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-6-metylpyridin-2-karbonitril;
- 4-[7-(piperazin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;
- 15 4-[7-(4-acetylpiperazin-1-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl]benzonitril;
- 4-{7-[(2,3-dihydroksypropyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-
metylbenzonitril;
- N*-[5-(4-cyano-3-fluor-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-
yl]acetamid;
- 20 4-{7-klor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2,3-difluorbenzonitril;
- 4-{7-klor-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2-fluor-5-metylbenzonitril;
- N*-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]formamid;
- 6-amino-5-{[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-pyridin-2-karbonitril;

N-[5-(4-cyano-2-metylfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-hydroksyacetamid;

N-[5-(4-cyano-2-metylfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-3,3,3-trifluor-2-hydroksypropanamid;

5 *N*-[5-(4-cyano-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2-hydroksy-2-metylpropanamid;

N-[5-(6-cyano-2-metylpyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

10 *tert*-butyl-*N*-[5-(4-cyano-2-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]karbamat;

N-[5-(4-cyano-3-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]oksetan-2-karboksamid;

N-[5-(4-cyano-2-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

15 *N*-[5-(4-cyano-2-fluorfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-karboksamid;

3-fluor-4-{7-[(2-metoksyetyl)amino]-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}benzonitril;

N-[5-(6-cyano-4-metylpyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

20 5-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-4-metyl-pyridin-2-karbonitril;

4-{7-hydroksy-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-metylbenzonitril;

N-[5-(4-cyano-2-metylfenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropan-karboksamid;

5-{7-hydroksy-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-6-metylpyridin-2-karbonitril;

25 3-metyl-4-(7-{2-oksa-6-azaspiro[3.3]heptan-6-yl}-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl)benzonitril;

N-[5-(6-cyano-2-metylpyridin-3-yl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]cyklopropankarboksamid;

4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3,5-difluorbenzonitril;

5 *N*-[5-(4-cyano-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]-2,2-difluorcyklopropan-1-karboksamid;

4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-3-klorbenzonitril;

4-{7-amino-[1,2,4]triazolo[1,5-*a*]pyridin-5-yl}-2,3-difluorbenzonitril;

N-[5-(2-klor-4-cyanofenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid; eller

10 *N*-[5-(4-cyano-5-fluor-2-metyl-fenyl)-[1,2,4]triazolo[1,5-*a*]pyridin-7-yl]acetamid;

eller et farmasøytisk akseptabelt salt derav.

11. Farmasøytisk sammensetning som omfatter en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav, ifølge krav 1, i forbindelse med en
15 farmasøytisk akseptabel adjuvans, fortynningsmiddel eller bærer, og eventuelt ett eller flere andre terapeutiske midler.

12. Farmasøytisk sammensetning ifølge krav 11, som er en PHD-inhibitor.

20 13. Farmasøytisk sammensetning ifølge krav 11, som er et middel for behandling av akutt nyreskade, kronisk nyresykdom, akutt dekompensert hjertesvikt, hjertesvikt etter et hjerteinfarkt eller perifer arteriesykdom.

25 14. Forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav ifølge krav 1, for anvendelse i terapi.

15. Forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav ifølge krav 1, for anvendelse i behandling av akutt nyreskade, kronisk nyresykdom, akutt dekompensert hjertesvikt, hjertesvikt etter et hjerteinfarkt eller perifer arteriesykdom.